August 22, 2003

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Revisions to the Immunization Program

Please note the following changes to the Immunization Program:

(1) Section II Immunization Schedules

Page 7, Vaccines recommended for high risk clients:

- meningococcal conjugate and meningococcal polysaccharide vaccines are recommended for recipients of solid organ transplants.

Pages 8, 10, 11, and 12, Immunization Schedules:

- for clarity, names of the biological products containing diphtheria/pertussis/tetanus have been written in full, rather than only abbreviated.

Page 11, Schedule C:

- timing for third dose of TdaP is twelve months after the second visit.

Page 13, Schedule E:

- clarification regarding eligibility of adults for polio booster.

Administrative Circular: 2003:11
(2) Section VII Biological Products

Page 5, Haemophilus B Conjugate Vaccine (Act-HIB®):

- the second indication for this vaccine now specifies "unimmunized" persons older than 5 years of age with the listed conditions.
- the third indication for the vaccine separates out recipients of hematopoietic stem cell transplants (HSCT) as this group requires 3 doses of Hib vaccine.

Page 7, Hepatitis A Vaccine (Havrix®):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.
- addition of Avaxim™ Pediatric as another interchangeable hepatitis A vaccine (using age-specific dosage).

Page 8, Hepatitis A Vaccine (Vaqta®):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.
- In the footnotes: addition of Avaxim™ Pediatric as another interchangeable hepatitis A vaccine (using age-specific dosage).

Page 9, Hepatitis A Vaccine (Avaxim™):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.
- addition of Avaxim™ Pediatric as another interchangeable hepatitis A vaccine (using age-specific dosage).

Page 9a, Hepatitis A Vaccine (Avaxim™ Pediatric):

- new page, product licensed for age 12 months to 15 of years inclusive.

Page 10, Hepatitis A Vaccine (Epaxal Berna®):

- addition of Avaxim™ Pediatric as another interchangeable hepatitis A vaccine (using age-specific dosage).
Page 12, Hepatitis B Immune Globulin (Bayhep B™):

- addition of anaphylactic reaction to latex as a precaution to this biological product.
- the ventrogluteal site can be used for those > 7 months of age. However, the vastus lateralis is most often used for infants and children up to 5 years of age.

Page 18, Hepatitis B Vaccine (RecombivaxHB®):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.

Page 24, Hepatitis A and B Vaccine Combined (Twinrix™):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.
- addition of Avaxim™ Pediatric as another interchangeable hepatitis A vaccine (using age-specific dosage).

Page 25, Hepatitis A and B Vaccine Combined (Twinrix Junior™):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.
- addition of Avaxim™ Pediatric as another interchangeable hepatitis A vaccine (using age-specific dosage).

Page 27, Immune Globulin (Baygam™):

- addition of anaphylactic reaction to latex as a precaution to this biological product.
- the ventrogluteal site can be used for those >7 months of age. However, the vastus lateralis is most often used for infants and children up to 5 years of age.

Page 34, Measles/Mumps/Rubella Vaccine (Priorix™):

- addition of anaphylactic reaction to latex as a contraindication to Priorix™ vaccine (pre-filled syringe of diluent).
Page 37, Meningococcal C Conjugate Vaccine (Neis Vac-C):

- addition of grade 6 students as a group eligible for this vaccine.

Pages 39 and 40, Meningococcal Polysaccharide Vaccine (Menomune®):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.

Page 41, Pneumococcal Conjugate Vaccine (Prevnar™):

- revised footnote ♠ regarding completion of immunization when the primary series has been interrupted.
- addition of anaphylactic reaction to latex as a contraindication to this vaccine.

Page 41a, Completion of primary series when conjugate pneumococcal vaccination has been interrupted (healthy or high risk children):

- this is a new page that specifies the scheduling of conjugate pneumococcal vaccination when the primary series has been interrupted.

Page 42, Recommendations for Pneumococcal Immunization With 7-Valent Pneumococcal Conjugate Vaccine (PCV 7) and 23-Valent Pneumococcal Polysaccharide Vaccine (PPV 23) for Children at High Risk of Pneumococcal Disease:

- revisions made to be consistent with page 41a.
- addition of anaphylactic reaction to latex as a contraindication for Prevnar™ and Pneumo 23™.

Page 43, Pneumococcal Polysaccharide Vaccine (Pneumo 23™):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.

Page 44, Polio Vaccine:

- clarification regarding booster dose for travelers to endemic areas.
Page 45, Human Rabies Immune Globulin (HRIG) (Imogam®):

- information pertaining to site of administration has been made consistent with recommendations in the Rabies Control Guidelines. The ventrogluteal site can be used for those > 7 months of age. However, the vastus lateralis is most often used for infants and children up to 5 years of age.

Page 46, Human Rabies Immune Globulin (HRIG) (Imogam®):

- addition of anaphylactic reaction to latex as a precaution to this biological product.

Pages 47 and 50, Rabies Vaccine (Imovax® Rabies):

- addition of anaphylactic reaction to latex as a contraindication/precaution to this vaccine.

Page 52, Tetanus-Diphtheria (Td) Adsorbed:

- addition of anaphylactic reaction to latex as a contraindication to this vaccine (multidose vial presentation).

Page 53, Tetanus-Diphtheria-acellular Pertussis Vaccine (TdaP):

- the word “individuals” replaces “children” for clarification re: vaccine eligibility.

Page 55, Tetanus Immune Globulin (TIG) Baytet™:

- addition of anaphylactic reaction to latex as a precaution to this biological product.
- the ventrogluteal site can be used for those > 7 months of age. However, the vastus lateralis is most often used for infants and children up to 5 years of age.

Page 59, Typhoid Vaccine (Typhim Vi™):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.
Page 61, Typhoid Vaccine (Typherix™):

- addition of anaphylactic reaction to latex as a contraindication to this vaccine.

Page 62, Varicella Zoster Immune Globulin (VZIG):

- the ventrogluteal site can be used for those >7 months of age. However, the vastus lateralis is most often used for infants and children up to 5 years of age.

Please remove and destroy the following pages from the Immunization Chapter of the Communicable Disease Control Manual:

Section II
Pages 7, 8, 10, 11, 12 & 13 Dated June 2003

Section VII
Table of Contents Dated June 2003
Pages 5, 12, 25, 43, 45, 46, 52, 55, 59, 61, & 62 Dated March 2003
Pages 24, 37, 39, 40, 41, 42 & 53 Dated June 2003
Pages 7, 8, 9, 10, 18, 27, 34, 44, 47, & 50 Dated November 2002

Insert the following pages in the Immunization Chapter:

Section II
Pages 7, 8, 10, 11, 12 & 13 Dated August 2003

Section VII
Table of Contents Dated August 2003
Pages 5, 7, 8, 9, 9a, 10, 12, 18, 24, 25, 27, 34, 37, 39, 40, 41, 41a, 42, 43, 44, 45, 46, 47, 50, 52, 53, 55, 59, 61, & 62 Dated August 2003
These revisions to the Immunization Chapter of the Communicable Disease Control Manual are posted on the BCCDC website at: www.bccdc.org

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604) 660-6061, fax (604) 660-0197 or e-mail karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca.

Sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control

DMP/kka

pc:    Dr Perry Kendall          Dr. Shaun Peck
       Provincial Health Officer    Deputy Provincial Health Officer
       Ministry of Health Services  Ministry of Health Services

       Dr. Bob Fisk                Lorna Storbakken
       Medical Consultant         Director
       Non-Communicable Disease   Disease and Injury Prevention Branch
       Services                  Ministry of Health Planning

       Jane Crickmore             Ministry of Health Planning
       Public Health Nursing Consultant
       Disease and Injury Prevention Branch
       Ministry of Health Planning